Comment on: “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022”

Sieta T. Vries (), Noral Huda S. Al-Mugoter (), Irena Petkoska (), Stefan Verweij (), André J. A. Elferink () and Peter G. M. Mol ()
Additional contact information
Sieta T. Vries: Dutch Medicines Evaluation Board
Noral Huda S. Al-Mugoter: Dutch Medicines Evaluation Board
Irena Petkoska: Dutch Medicines Evaluation Board
Stefan Verweij: Dutch Medicines Evaluation Board
André J. A. Elferink: Dutch Medicines Evaluation Board
Peter G. M. Mol: Dutch Medicines Evaluation Board

Applied Health Economics and Health Policy, 2024, vol. 22, issue 1, No 12, 123-124

Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-023-00850-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:22:y:2024:i:1:d:10.1007_s40258-023-00850-4

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-023-00850-4

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().